Cencora Beats Q3 Estimates, Raises FY26 EPS Guidance on Specialty Strength
COR sits 30% above its 52-week low of $244.82.
Summary
Cencora delivered a strong Q3, with adjusted EPS of $4.48 beating the $4.35 consensus and revenue of $84.75B topping estimates. Gross profit jumped 24% to $3.6B, driven by the OneOncology acquisition and favorable LIFO credits, though GLP-1 sales pressured margins. The company raised its full-year adjusted EPS guidance to $17.75-$17.95, up from $17.70-$17.90, and affirmed its revenue outlook. This follows the earlier Q3 8-K filing and builds on the May guidance raise and $2B buyback announcement. The specialty pipeline and international expansion are delivering, but the GLP-1 margin drag is a watchpoint for future quarters.
At the time of this announcement, COR was trading at $318.28 on NYSE in the Trade & Services sector, with a market capitalization of approximately $61.9B. The 52-week trading range was $244.82 to $377.54. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.